BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 22262778)

  • 1. Unique features of primary myelofibrosis in Chinese.
    Xu Z; Gale RP; Zhang Y; Qin T; Chen H; Zhang P; Zhang T; Liu L; Qu S; Xiao Z
    Blood; 2012 Mar; 119(11):2469-73. PubMed ID: 22262778
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Frequency and allele burden of CALR mutations in Chinese with essential thrombocythemia and primary myelofibrosis without JAK2(V617F) or MPL mutations.
    Li N; Yao QM; Gale RP; Li JL; Li LD; Zhao XS; Jiang H; Jiang Q; Jiang B; Shi HX; Chen SS; Liu KY; Huang XJ; Ruan GR
    Leuk Res; 2015 May; 39(5):510-4. PubMed ID: 25746303
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of JAK2
    Latagliata R; Polverelli N; Tieghi A; Palumbo GA; Breccia M; Sabattini E; Villari L; Riminucci M; Valli R; Catani L; Alimena G; Ottaviani E; Fama A; Martinelli G; Perricone M; Spinsanti M; Cavo M; Vianelli N; Palandri F
    Hematol Oncol; 2018 Feb; 36(1):269-275. PubMed ID: 28509339
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Improved Survival of Calreticulin-Mutated Patients Compared With Janus Kinase 2 in Primary Myelofibrosis: A Meta-Analysis.
    Kourie HR; Ameye L; Paesmans M; Bron D
    Clin Lymphoma Myeloma Leuk; 2016 May; 16(5):264-8. PubMed ID: 26935576
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Prognostic value of JAK2, MPL and CALR mutations in Chinese patients with primary myelofibrosis].
    Xu ZF; Li B; Liu JQ; Li Y; Ai XF; Zhang PH; Qin TJ; Zhang Y; Wang JY; Xu JQ; Zhang HL; Fang LW; Pan LJ; Hu NB; Qu SQ; Xiao ZJ
    Zhonghua Xue Ye Xue Za Zhi; 2016 Jul; 37(7):576-80. PubMed ID: 27535857
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Calreticulin mutations in Chinese with primary myelofibrosis.
    Li B; Xu J; Wang J; Gale RP; Xu Z; Cui Y; Yang L; Xing R; Ai X; Qin T; Zhang Y; Zhang P; Xiao Z
    Haematologica; 2014 Nov; 99(11):1697-700. PubMed ID: 24997152
    [TBL] [Abstract][Full Text] [Related]  

  • 7. JAK2 V617F, MPL, and CALR Mutations in Korean Patients with Essential Thrombocythemia and Primary Myelofibrosis.
    Kim BH; Cho YU; Bae MH; Jang S; Seo EJ; Chi HS; Choi Y; Kim DY; Lee JH; Lee JH; Lee KH; Park YM; Lee JK; Park CJ
    J Korean Med Sci; 2015 Jul; 30(7):882-8. PubMed ID: 26130950
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The clinical and prognostic relevance of driver mutations in 203 Taiwanese patients with primary myelofibrosis.
    Kuo MC; Lin TH; Sun CF; Lin TL; Wu JH; Wang PN; Huang YJ; Chang H; Huang TY; Shih LY
    J Clin Pathol; 2018 Jun; 71(6):514-521. PubMed ID: 29203554
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Primary myelofibrosis with or without mutant MPL: comparison of survival and clinical features involving 603 patients.
    Pardanani A; Guglielmelli P; Lasho TL; Pancrazzi A; Finke CM; Vannucchi AM; Tefferi A
    Leukemia; 2011 Dec; 25(12):1834-9. PubMed ID: 21691276
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evidence that prefibrotic myelofibrosis is aligned along a clinical and biological continuum featuring primary myelofibrosis.
    Barosi G; Rosti V; Bonetti E; Campanelli R; Carolei A; Catarsi P; Isgrò AM; Lupo L; Massa M; Poletto V; Viarengo G; Villani L; Magrini U
    PLoS One; 2012; 7(4):e35631. PubMed ID: 22536419
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mutations and long-term outcome of 217 young patients with essential thrombocythemia or early primary myelofibrosis.
    Palandri F; Latagliata R; Polverelli N; Tieghi A; Crugnola M; Martino B; Perricone M; Breccia M; Ottaviani E; Testoni N; Merli F; Aversa F; Alimena G; Cavo M; Martinelli G; Catani L; Baccarani M; Vianelli N
    Leukemia; 2015 Jun; 29(6):1344-9. PubMed ID: 25801912
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mutational subtypes of JAK2 and CALR correlate with different clinical features in Japanese patients with myeloproliferative neoplasms.
    Misawa K; Yasuda H; Araki M; Ochiai T; Morishita S; Shirane S; Edahiro Y; Gotoh A; Ohsaka A; Komatsu N
    Int J Hematol; 2018 Jun; 107(6):673-680. PubMed ID: 29464483
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CALR mutation screening in pediatric primary myelofibrosis.
    An W; Wan Y; Guo Y; Chen X; Ren Y; Zhang J; Chang L; Wei W; Zhang P; Zhu X
    Pediatr Blood Cancer; 2014 Dec; 61(12):2256-62. PubMed ID: 25176567
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic impact of splenomegaly on survival of Chinese with primary myelofibrosis.
    Wang J; Xu J; Gale RP; Xu Z; Li B; Qin T; Zhang Y; Fang L; Zhang H; Pan L; Qu S; Zhang P; Xiao Z
    Leuk Res; 2014 Oct; 38(10):1207-11. PubMed ID: 25182689
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Utility of JAK2 V617F allelic burden in distinguishing chronic myelomonocytic Leukemia from Primary myelofibrosis with monocytosis.
    Hu Z; Ramos CEB; Medeiros LJ; Zhao C; Yin CC; Li S; Hu S; Wang W; Thakral B; Xu J; Verstovsek S; Lin P
    Hum Pathol; 2019 Mar; 85():290-298. PubMed ID: 30447300
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A3669G polymorphism of glucocorticoid receptor is a susceptibility allele for primary myelofibrosis and contributes to phenotypic diversity and blast transformation.
    Poletto V; Rosti V; Villani L; Catarsi P; Carolei A; Campanelli R; Massa M; Martinetti M; Viarengo G; Malovini A; Migliaccio AR; Barosi G
    Blood; 2012 Oct; 120(15):3112-7. PubMed ID: 22879541
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pre-fibrotic/early primary myelofibrosis vs. WHO-defined essential thrombocythemia: The impact of minor clinical diagnostic criteria on the outcome of the disease.
    Jeryczynski G; Thiele J; Gisslinger B; Wölfler A; Schalling M; Gleiß A; Burgstaller S; Buxhofer-Ausch V; Sliwa T; Schlögl E; Geissler K; Krauth MT; Nader A; Vesely M; Simonitsch-Klupp I; Müllauer L; Beham-Schmid C; Gisslinger H
    Am J Hematol; 2017 Sep; 92(9):885-891. PubMed ID: 28543356
    [TBL] [Abstract][Full Text] [Related]  

  • 18. JAK-2 V617F Mutational Analysis in Primary Idiopathic Myelofibrosis: Experience from Southern Pakistan.
    Sultan S; Irfan SM
    Asian Pac J Cancer Prev; 2015; 16(17):7889-92. PubMed ID: 26625816
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic implications of low transferrin saturation in patients with primary myelofibrosis.
    Lucijanic M; Prka Z; Pejsa V; Stoos-Veic T; Lucijanic J; Kusec R
    Leuk Res; 2018 Mar; 66():89-95. PubMed ID: 29407589
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Molecular Pathogenesis and Clinical Significance of Driver Mutations in Primary Myelofibrosis: A Review.
    Alshemmari SH; Rajan R; Emadi A
    Med Princ Pract; 2016; 25(6):501-509. PubMed ID: 27756071
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.